Capital One Financial Comments on IDEAYA Biosciences, Inc.’s FY2028 Earnings (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a clinical-stage biotechnology company focused on developing novel therapies for cancer and rare diseases. The company's lead program, IGNITE-1, is a Phase 2 trial evaluating the safety and efficacy of its proprietary immunotherapy candidate, IGN-101, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

In a report released on Thursday, February 22nd, Capital One Financial analyst T. Chiang issued his FY2028 earnings per share (EPS) estimates for shares of IDEAYA Biosciences. According to the report, Chiang expects the company to post earnings of $4.54 per share for the fiscal year ending December 31, 2028.

It's important to note that these EPS estimates are based on several assumptions and may be subject to change as the company progresses through its clinical trials and other developments. Additionally, the company has not yet reported any financial results for FY2028, so these estimates are purely speculative at this time.

Overall, IDEAYA Biosciences is a promising biotechnology company with a focus on developing innovative therapies for cancer and rare diseases. While the company's future financial performance is uncertain, its lead program, IGNITE-1, has shown promising results in early clinical trials and could potentially lead to significant revenue for the company if approved by regulatory agencies.